News | September 08, 2010

Ticagrelor Demonstrates Advantages Over Clopidogrel

September 8, 2010 – The increased effectiveness of ticagrelor (Brilinta) in overcoming high platelet reactivity as compared to the gold-standard of clopidogrel (Plavix) was shown in data presented last week at the European Society of Cardiology (ESC) Congress in Stockholm.

Pooled pharmacologic data from the ONSET/OFFSET and RESPOND trials compared high platelet reactivity between clopidogrel and ticagrelor use. This reactivity has been linked to complications following percutaneous coronary intervention (PCI).

Ticagrelor showed better platelet inhibition and faster offset than clopidogrel in the ONSET/OFFSET study. The RESPOND study also confirmed better platelet inhibition with ticagrelor in both clopidogrel responders and nonresponders. The effects of ticagrelor were observed within two hours, while clopidogrel took between four and eight hours.

One of the chief advantages of ticagrelor is its ability to reverse its effects quickly as compared to clopidogrel, which was also demonstrated in these data.

In July, the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee voted to recommend that the FDA approve ticagrelor for the reduction of thrombotic events in patients with acute coronary syndromes (ACS). The panel reviewed data from the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study, an outcomes trial of more than 18,000 patients whose data showed ticagrelor was superior to clopidogrel in the long-term reduction of cardiovascular events.

The FDA is expected to make an approval decision this month.

Related Content

Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Overlay Init